Design and synthesis of tricyclic benzo[1, 3]oxazinyloxazolidinones as blood coagulation factor Xa inhibitors

Abstract The coagulation enzyme factor Xa (FXa) is a valuable target for developing anticoagulants to treat thrombotic diseases. In this work, we designed and synthesized a series of conformationally restricted compounds containing the benzo[1,3]oxazinyloxazolidinone scaffold. The target compounds were synthesized by 11 steps reaction. The preliminary SAR showed that on the phenyl ring of benzo[1,3]oxazinyloxazolidinone, lactam replacements at the 6-position were favorable for FXa inhibition. Compound 16b showed good FXa inhibitory activity with an IC50 of 0.43 μM. The results indicate that benzo[1,3]oxazinyloxazolidinone is a promising scaffold for developing FXa inhibitors as antithrombotic agents. Graphical Abstract

[1]  Yu Lu,et al.  Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens. , 2021, Journal of medicinal chemistry.

[2]  Dongwei Kang,et al.  Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors , 2019, Expert opinion on drug discovery.

[3]  P. Murumkar,et al.  Advances in the Development of Novel Factor Xa Inhibitors: A Patent Review. , 2018, Mini reviews in medicinal chemistry.

[4]  Loreto P. Parra,et al.  Surfing the Blood Coagulation Cascade: Insight into the Vital Factor Xa. , 2018, Current medicinal chemistry.

[5]  M. Díaz-Ricart,et al.  Betrixaban: a direct oral inhibitor of activated factor X for the prophylaxis of venous thromboembolism in patients hospitalized for acute medical illness. , 2017, Drugs of today.

[6]  P. Murumkar,et al.  Contemporary developments in the discovery of selective factor Xa inhibitors: A review. , 2016, European journal of medicinal chemistry.

[7]  P. Gong,et al.  Design, synthesis and structure-activity relationship of oxazolidinone derivatives containing novel S4 ligand as FXa inhibitors. , 2015, European journal of medicinal chemistry.

[8]  Wenjing Chu,et al.  Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor. , 2014, Journal of medicinal chemistry.

[9]  A. V. Varlamov,et al.  General synthetic approach towards annelated 3a,6-epoxyisoindoles by tandem acylation/IMDAF reaction of furylazaheterocycles. Scope and limitations , 2014 .

[10]  G. Raskob,et al.  ISTH Steering Committee for World Thrombosis Day The members of the ISTH Steering Committee for World Thrombosis Day , 2014 .

[11]  D. Kubitza,et al.  The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor , 2011, Nature Reviews Drug Discovery.

[12]  D. Cheney,et al.  Factor Xa inhibitors: next-generation antithrombotic agents. , 2010, Journal of medicinal chemistry.

[13]  Thomas Lampe,et al.  Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. , 2005, Journal of medicinal chemistry.

[14]  K. Schlemmer,et al.  In vitro and in vivo studies of the novel antithrombotic agent BAY 59‐7939—an oral, direct Factor Xa inhibitor , 2005, Journal of thrombosis and haemostasis : JTH.

[15]  P. Merino,et al.  A straightforward synthesis of L-isoserinal , 1996 .

[16]  D. Norbeck,et al.  Application of the Swern oxidation to the manipulation of highly reactive carbonyl compounds , 1985 .